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Rabies kills tens of thousands of people every year despite being entirely vaccine preventable. Key global
health actors have launched a country-driven plan to achieve zero human deaths from dog-mediated
rabies by 2030 worldwide. This partnership has recently been strengthened by Gavi, the Vaccine
Alliance’s decision to invest in human rabies vaccines for post-exposure prophylaxis (PEP). While nation
states are key to rabies elimination, the importance of Gavi’s role cannot be understated. Unlike any other
actor, Gavi can directly address an otherwise intractable market failure in the inadequate supply of rabies
PEP. In this commentary, we employ the Capabilities Approach to identify the barriers to PEP access that
lead to this market failure and, as a result, unnecessary deaths and suffering. We show the role that Gavi
can play in reducing exposure of PEP supply to market forces as a matter of social justice, and hence
redress the inequity underlying human rabies deaths.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY IGO license. (http://crea-
tivecommons.org/licenses/by/3.0/igo/).Canine rabies kills tens of thousands of people every year
despite being a disease that is entirely vaccine preventable, and
one for which effective vaccines have existed for over a century
[1]. Mass dog vaccination has led to the elimination of rabies
spread by domestic dogs from high-income countries. Rabies
now remains as a disease of impoverished communities in low-
and middle-income countries (LMICs). More than 95% of deaths
occur in Africa and Asia, and mostly among people living in rural,
underserved populations where dog vaccination is rare [2]. Follow-
ing a rabid dog bite, prompt post-exposure prophylaxis (PEP) is the
only way to ensure the invariably fatal onset of rabies is prevented
[3]. Modelling suggests that without scaled up dog vaccination and
under current PEP access, over 1 million people will die of dog-
mediated rabies between 2020 and 2035 [4]. Mass dog vaccination
is essential for the elimination of canine rabies, but here we
address the role of PEP provision.
In June 2018, the World Health Organization (WHO), the World
Organisation for Animal Health (OIE), the Food and Agriculture
Organization of the United Nations (FAO) and the Global Alliance
for Rabies Control (GARC) came together to launch a country-
driven ‘Global Strategic Plan’ to achieve zero human deaths fromdog-mediated rabies by 2030 [5]. This was recently given a mas-
sive boost when Gavi, the Vaccine Alliance, announced their deci-
sion to invest in human rabies vaccine for PEP [6]. While nation
states are key to rabies elimination, as shown by examples from
Latin America, South Africa, and Sri Lanka using existing knowl-
edge, tools and technology [5], the importance of Gavi’s role cannot
be understated. Unlike any other global or state actor, Gavi can
directly address an otherwise intractable market failure in the sup-
ply of PEP. Market forces do not always serve LMICs well, where
uncertain funding and demand for vaccines do not provide manu-
facturers with sufficient incentive to invest in products at afford-
able prices. Gavi has the power to ‘shape’ the market for human
rabies vaccines.
In this commentary, we employ the Capabilities Approach to
identify barriers to PEP access that lead to this market failure
and show the role that Gavi can play in reducing exposure of PEP
supply to market forces. The Capabilities Approach is concerned
with what people are able to do and what lives they are able to
lead. Only by assessing an individual’s capabilities can their real
quality of life be determined. Applying the Approach is to identify
the social arrangements that enable and impede people from ful-
filling their capability [7,8]. People in LMICs have their capability
to good health that is free from rabies constrained because of mar-
ket and state failure to ensure PEP access. This is however not a
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Approach is a normative theory of social justice that places a fun-
damental value on health and equity and advocates a fairer distri-
bution of health capabilities. Traditional health policy making in
contrast is largely dominated by a utilitarian approach, advocating
social arrangements to maximise aggregate utility without directly
taking account of distributional concerns [9]. This justifies large
inequalities if an improvement in aggregate welfare is the end
result [10]. This is the reason why rabies deaths occur mostly in
LMICs and in the poorest communities even though these deaths
are preventable through timely access to PEP. The Capabilities
Approach provides a framework for including factors affecting an
individual’s ability to access PEP in multiple and diverse contexts.
In addition to the availability of PEP, it takes into account structural
factors such as socioeconomic status, access to education, ability to
travel or geographical location, country infrastructure, and other
aspects of service provision that may have a role. In this way, the
Capabilities Approach reveals the mechanisms by which inequity
and injustice is manifested, which we outline below for PEP access
to prevent human rabies.
Deep-rooted structural barriers across individual, national and
global scales underpin the problem of limited PEP access. Strate-
gies advocated by the World Bank, such as structural adjustment
programmes and the introduction of user charges have widened
health inequalities and inadvertently weakened service provision
[11]. Bite victims in many LMICs face out-of-pocket costs of at least
$10 per vaccine dose [12], and oftentimes over $100 for a multi-
dose course [13], costs that are prohibitive for poor households.
Health insurance schemes attempt to mitigate these costs, but only
a small fraction of LMIC citizens have effective health insurance
[14]. Moreover, these costs are compounded by travel; vaccines
are usually only available in urban centres and in some countries
only capital cities [12,13,15–19].
The lack of proper organization is also a key issue. Many LMICs
still lack a national rabies programme [19]. At the same time, poli-
cies of decentralization have led many countries to devolve cost
recovery responsibilities to local authorities. Much healthcare pri-
ority setting at the subnational level is often ad hoc [20]. Local bud-
gets are usually allocated to cheaper medicines at the expense of
less frequently used but, in the case of rabies, life-saving vaccines
[12]. Thus without adequate PEP pre-financing (or aligned cost
recovery), bite victims are either deferred to central hospitals
where vaccines may be available [18], or there is a scramble to
obtain vaccine from private providers [12,16]. Under these circum-
stances and a lack of regulatory oversight (transparent mecha-
nisms accounting for vaccine use) the market price increases,
leading to delays for patients and introducing a risk of PEP failure
[4]. Inflated price for vaccines, including for non-pre-qualified vac-
cines of unassured quality [16], is left to the most vulnerable: bite
victims and their families who are least able to pay, yet are facing a
life or death situation [4]. Some suppliers are unwilling to provide
vaccines if local authorities are indebted [12]. Insufficient procure-
ment has been reported in several sub-Saharan countries to cause
chronic stockouts [12,16,18]. The divergence of local health prior-
ities from national priorities leads to individualized, sporadic and
inadequate responses rather than a coherent population-level
response. The reality is that PEP supply in many LMICs is not
aligned with global recommendations or national strategies, and
as such is neither functional nor responsive for those in need.
Global rabies policy has lacked coherence and translation into
practice further constraining PEP access. A bewildering range of
intramuscular and intradermal post-exposure regimens are con-
sidered safe and effective, each requiring different doses and clinic
visits per course [21]. Intradermal vaccination uses considerably
less vaccine per patient, enables more patients to be treated with
the same vaccine volume (alleviating shortages), and is alreadyroutinely used for childhood BCG vaccination [21]. Yet, intradermal
rabies post-exposure vaccination has not been widely adopted.
Moreover, despite more than 30 years of evidence on the efficacy
of intradermal post-exposure vaccination [22], pharmaceuticals
have not added the route to their rabies vaccine labels. The com-
plexity of regimens, minimal advertising of intradermal vaccina-
tion, and lack of simplified recommendations has contributed to
inadequate PEP provision and confusion. Health workers in many
LMICs are not aware of the intradermal option for rabies vaccina-
tion, with a lack of translation from international to local guide-
lines. Collectively, these barriers act as constraints on the ability
to convert resources into functionings, known in the Capabilities
Approach as ‘Conversion Factors’ [23]. Life-saving PEP exists but
because of constrained access, the vulnerable lack real opportunity
to health.
The latest WHO position on rabies creates an opportunity for
harmonisation and global action [3]. The WHO now recommends
a new dose sparing abridged intradermal regimen that uses just
0.6 mL of vaccine per course (less than all other regimens). It is
completed in just one week [24]. Policies have been aligned to
improve access to PEP [3]. The economic case is clear; adoption
of WHO policies would be cost equivalent to the status quo [4].
Indeed current vaccine production could meet projected demand,
reaching millions more people, through a switch to the recom-
mended abridged intradermal regimen. But for social justice to
be achieved and the WHO position to be realized, market shaping
is required to overcome structural barriers and facilitate improved
health seeking and adherence that would save many lives [4].
Making PEP free at point of care, as routine vaccines are, would
immediately circumvent financial constraints on individuals and
governments, and also reassure vaccine suppliers operating in
LMICs. Beyond this, Gavi’s investment could bring health system
benefits such as increased capacity for surveillance of human
rabies exposures, deaths and accountable use of PEP that has been
neglected for rabies. It also should create a translational opportu-
nity for training healthcare workers to implement the new guide-
lines. Gavi investment has strengthened health systems and
transparent supply chains for many vaccines, whereas systems
for forecasting, procuring, distributing and monitoring rabies vac-
cines are mostly non-existent, inconsistent, and unresponsive
[12,16,19]. Strengthened health systems improves equity and
access to healthcare, and contributes towards long-term sustain-
able development. Bite victims will be able to overcome structural
barriers to PEP access and fulfill their capability to health through
avoidance of death from rabies.
The case for Gavi investment from a utilitarian cost-
effectiveness perspective has been made elsewhere [4]. Using the
Capabilities Approach, we make a normative argument by showing
how the status quo of PEP supply is an unjust one. We have shown
how those most at risk and in most need of rabies vaccines, face
structural barriers which constrain their capabilities to a good
health free from rabies. These barriers have also constrained their
agency and political voice to advocate for change. Until recently, no
powerful actors have led on policy change that could facilitate
improved PEP access. Indeed, neither governments nor pharma-
ceuticals are incentivized to drive this change under current mar-
ket forces. To overcome this persistent market failure in LMICs,
Gavi’s investment could now redistribute the costs from those least
able to pay, to global actors. This could also empower local social
actors, from local communities to NGOs, to educate and help mobi-
lise bite victims into seeking the care they need. This will change a
currently unjust status quo, and help prevent the poorest from suf-
fering disproportionately and dying unnecessarily from rabies.
While we recognise that the impact of global health initiatives
play out in highly complex local realities, Gavi’s investment now
potentially transforms a source of structural inequity in rabies
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harnesses the potential that the SDGs offer [25]- an intervention
that addresses both upstream and downstream causes of ill health.
Improved PEP access should allow countries to redistribute
resources within the health system. Moreover, drawing upon a col-
laborative One Health approach [26], we foresee more countries
effectively leveraging on existing knowledge, tools and technology
that others have already shown to be effective for rabies elimina-
tion [5]. This ought to catalyze mass dog vaccination programmes
to eliminate rabies from source populations - the most equitable of
solutions.
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